A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine ...

However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...

Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...

Adjuvant aromatase inhibitor therapy is well established in postmenopausal women with hormone receptor–positive breast cancer, but such therapy is complicated by accelerated bone loss and increased ...

Dear Dr. Roach: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.